Thermo Fisher Scientific Inc. $TMO Shares Acquired by Andra AP fonden

Andra AP fonden boosted its stake in Thermo Fisher Scientific Inc. (NYSE:TMO) by 25.3% in the second quarter, Holdings Channel.com reports. The fund owned 72,457 shares of the medical research company’s stock after buying an additional 14,643 shares during the quarter. Andra AP fonden’s holdings in Thermo Fisher Scientific were worth $36,327,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other hedge funds also recently made changes to their positions in TMO. BlackRock Inc. acquired a new stake in shares of Thermo Fisher Scientific in the 2nd quarter valued at about $15,501,867,000. State Street Corp lifted its stake in Thermo Fisher Scientific by 1.4% in the fourth quarter. State Street Corp now owns 16,613,761 shares of the medical research company’s stock valued at $9,633,991,000 after buying an additional 229,630 shares during the last quarter. Corient Private Wealth LP acquired a new stake in shares of Thermo Fisher Scientific in the second quarter valued at approximately $382,547,000. Capital World Investors increased its holdings in shares of Thermo Fisher Scientific by 7.0% in the 4th quarter. Capital World Investors now owns 11,003,814 shares of the medical research company’s stock valued at $6,376,229,000 after acquiring an additional 718,669 shares during the period. Finally, Geode Capital Management LLC raised its position in Thermo Fisher Scientific by 0.3% in the 4th quarter. Geode Capital Management LLC now owns 8,196,477 shares of the medical research company’s stock valued at $4,728,129,000 after purchasing an additional 26,425 shares during the last quarter. Hedge funds and other institutional investors own 89.23% of the company’s stock.

Key Thermo Fisher Scientific News

Here are the key news stories impacting Thermo Fisher Scientific this week:

• Positive Sentiment: Goldman Sachs raised its price target on TMO to $780 from $650 and maintained a Buy rating. The significantly higher target reinforces the view that Thermo Fisher’s earnings momentum and long-term growth prospects justify additional upside. Goldman Sachs Adjusts Price Target on Thermo Fisher Scientific
• Positive Sentiment: Thermo Fisher is partnering with Mayo Clinic on Precure, an initiative designed to generate population-scale molecular data. The project could support future diagnostics, therapies and other healthcare products while strengthening TMO’s position in genomics, multi-omics and data-enabled medicine. Ultima Genomics was selected to provide sequencing technology for the one-million-sample dataset. Mayo Clinic and Thermo Fisher Partner to Create Precure
• Positive Sentiment: Industry reports point to expanding markets relevant to Thermo Fisher. ADME-toxicology testing, high-content screening, drug-discovery informatics and automated cell-therapy processing are forecast to grow substantially through the end of the decade. These reports are not new contracts or guidance changes, but they support the long-term demand outlook for TMO’s research and bioprocessing businesses. ADME-Toxicology Testing Market Report
• Neutral Sentiment: Although TMO recently outperformed over six months on strong quarterly results, it has still lagged the broader market in the latest session. The stock’s elevated valuation makes further gains increasingly dependent on sustained earnings growth. Thermo Fisher Stock Rises but Underperforms Market
• Negative Sentiment: A commentary titled “3 Reasons to Sell TMO” warns that the recent rally may have reduced the stock’s margin of safety, increasing downside risk if growth slows or expectations are missed. This is an opinion piece rather than a change in company fundamentals. 3 Reasons to Sell TMO

Analysts Set New Price Targets

A number of research firms have commented on TMO. KeyCorp restated an “overweight” rating on shares of Thermo Fisher Scientific in a research note on Tuesday, May 26th. Barclays raised their price target on Thermo Fisher Scientific from $625.00 to $650.00 and gave the stock an “overweight” rating in a report on Friday, July 24th. Citigroup cut Thermo Fisher Scientific from a “buy” rating to an “underperform” rating in a research report on Wednesday, September 9th. Wells Fargo & Company lowered Thermo Fisher Scientific from an “overweight” rating to an “underweight” rating in a report on Wednesday, September 9th. Finally, Morgan Stanley increased their price target on Thermo Fisher Scientific from $620.00 to $650.00 and gave the stock an “overweight” rating in a report on Friday, July 24th. Two research analysts have rated the stock with a Strong Buy rating, seventeen have issued a Buy rating, five have assigned a Hold rating and two have assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, Thermo Fisher Scientific currently has an average rating of “Moderate Buy” and an average target price of $624.64.

Thermo Fisher Scientific Price Performance

Shares of Thermo Fisher Scientific stock traded up $1.98 during trading on Tuesday, reaching $660.74. The company’s stock had a trading volume of 733,256 shares, compared to its average volume of 2,251,833. The business has a 50 day moving average price of $595.41 and a 200-day moving average price of $524.10. The company has a market capitalization of $244.31 billion, a P/E ratio of 35.56, a price-to-earnings-growth ratio of 2.72 and a beta of 0.85. The company has a quick ratio of 1.18, a current ratio of 1.55 and a debt-to-equity ratio of 0.74. Thermo Fisher Scientific Inc. has a 12-month low of $435.27 and a 12-month high of $663.57.

Thermo Fisher Scientific (NYSE:TMO) last issued its earnings results on Thursday, July 23rd. The medical research company reported $6.03 EPS for the quarter, topping the consensus estimate of $5.71 by $0.32. Thermo Fisher Scientific had a net margin of 15.04% and a return on equity of 17.09%. The company had revenue of $11.99 billion for the quarter, compared to analyst estimates of $11.71 billion. During the same period in the previous year, the firm earned $4.28 EPS. The business’s revenue was up 10.5% on a year-over-year basis. Thermo Fisher Scientific has set its FY 2026 guidance at 24.930-25.330 EPS. As a group, sell-side analysts anticipate that Thermo Fisher Scientific Inc. will post 25.13 EPS for the current year.

Thermo Fisher Scientific Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Thursday, October 15th. Stockholders of record on Tuesday, September 15th will be given a dividend of $0.47 per share. This represents a $1.88 dividend on an annualized basis and a dividend yield of 0.3%. The ex-dividend date is Tuesday, September 15th. Thermo Fisher Scientific’s dividend payout ratio (DPR) is presently 10.11%.

Insider Transactions at Thermo Fisher Scientific

In related news, VP Lisa P. Britt sold 11,440 shares of the stock in a transaction dated Wednesday, August 19th. The shares were sold at an average price of $613.12, for a total value of $7,014,092.80. Following the sale, the vice president directly owned 14,784 shares of the company’s stock, valued at approximately $9,064,366.08. This represents a 43.62% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, CAO Joseph R. Holmes sold 420 shares of Thermo Fisher Scientific stock in a transaction dated Friday, August 7th. The stock was sold at an average price of $584.81, for a total transaction of $245,620.20. Following the transaction, the chief accounting officer owned 2,966 shares of the company’s stock, valued at approximately $1,734,546.46. The trade was a 12.40% decrease in their position. The disclosure for this sale is available in the SEC filing. In the last 90 days, insiders have sold 73,768 shares of company stock worth $44,122,820. 0.33% of the stock is currently owned by insiders.

Thermo Fisher Scientific Company Profile

Thermo Fisher Scientific Inc is a global supplier of scientific equipment, laboratory services and analytical technologies. The company serves pharmaceutical and biotechnology companies, clinical laboratories, academic and government institutions, industrial businesses and other research organizations.

Its products and services include laboratory instruments, analytical systems, reagents, consumables, software and related services. Thermo Fisher also provides laboratory supplies and equipment, bioproduction solutions, genetic analysis technologies, clinical diagnostics, specialty diagnostic products and contract research and manufacturing services through its laboratory services businesses.

The company was formed in 2006 through the merger of Thermo Electron Corporation and Fisher Scientific International.